G. Pover

889 total citations
17 papers, 704 citations indexed

About

G. Pover is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, G. Pover has authored 17 papers receiving a total of 704 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 5 papers in Physiology. Recurrent topics in G. Pover's work include Colorectal Cancer Treatments and Studies (7 papers), Inhalation and Respiratory Drug Delivery (6 papers) and Asthma and respiratory diseases (5 papers). G. Pover is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Inhalation and Respiratory Drug Delivery (6 papers) and Asthma and respiratory diseases (5 papers). G. Pover collaborates with scholars based in United Kingdom, Hungary and United States. G. Pover's co-authors include Tudor–Eliade Ciuleanu, Phillip J. Stella, Constanta Timcheva, David R. Spigel, G. Bodoky, Niall C. Tebbutt, Clive Morris, Katalin Boér, István Láng and Valentina Tzekova and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology and Journal for ImmunoTherapy of Cancer.

In The Last Decade

G. Pover

16 papers receiving 692 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Pover United Kingdom 10 434 367 236 129 107 17 704
Tommasina Biscotti Italy 13 430 1.0× 182 0.5× 233 1.0× 208 1.6× 98 0.9× 21 690
Gemma Toledo Spain 12 187 0.4× 324 0.9× 173 0.7× 78 0.6× 57 0.5× 22 637
Masafumi Kataoka Japan 11 207 0.5× 252 0.7× 86 0.4× 84 0.7× 52 0.5× 39 514
Alexander Gaber Sweden 19 296 0.7× 365 1.0× 166 0.7× 224 1.7× 156 1.5× 29 791
Minaxi Jhawer United States 11 484 1.1× 305 0.8× 383 1.6× 98 0.8× 169 1.6× 14 842
Michela Quirino Italy 12 452 1.0× 240 0.7× 189 0.8× 77 0.6× 63 0.6× 27 767
Maria Rosa Cappelletti Italy 13 312 0.7× 213 0.6× 251 1.1× 239 1.9× 64 0.6× 32 635
Katherine L. Pogue–Geile United States 14 593 1.4× 209 0.6× 199 0.8× 233 1.8× 199 1.9× 44 870
Antonella Ingrosso Italy 14 244 0.6× 192 0.5× 163 0.7× 81 0.6× 61 0.6× 25 635
J. Wisell United States 12 291 0.7× 205 0.6× 84 0.4× 100 0.8× 56 0.5× 53 532

Countries citing papers authored by G. Pover

Since Specialization
Citations

This map shows the geographic impact of G. Pover's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Pover with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Pover more than expected).

Fields of papers citing papers by G. Pover

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Pover. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Pover. The network helps show where G. Pover may publish in the future.

Co-authorship network of co-authors of G. Pover

This figure shows the co-authorship network connecting the top 25 collaborators of G. Pover. A scholar is included among the top collaborators of G. Pover based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Pover. G. Pover is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Machiels, Jean‐Pascal, Ramón Salazar, Sylvie Rottey, et al.. (2019). A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). Journal for ImmunoTherapy of Cancer. 7(1). 20–20. 72 indexed citations
2.
3.
Hainsworth, John D., C. Cebotaru, Tudor–Eliade Ciuleanu, et al.. (2010). A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens. Journal of Thoracic Oncology. 5(10). 1630–1636. 134 indexed citations
4.
Boér, Katalin, István Láng, Antonio Llombart‐Cussac, et al.. (2010). Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study. Investigational New Drugs. 30(2). 681–687. 39 indexed citations
5.
6.
Horti, J, Anders Widmark, Arnulf Stenzl, et al.. (2009). A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer. Cancer Biotherapy and Radiopharmaceuticals. 24(2). 175–180. 39 indexed citations
7.
Oh, Do‐Youn, Rosine Guimbaud, J. Szántó, et al.. (2009). Vandetanib plus mFOLFOX6 in patients with advanced colorectal cancer (CRC): A randomized, double-blind, placebo-controlled phase II study. Journal of Clinical Oncology. 27(15_suppl). 4084–4084. 8 indexed citations
8.
Tzekova, Valentina, C. Cebotaru, Tudor–Eliade Ciuleanu, et al.. (2008). Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 26(15_suppl). 8029–8029. 19 indexed citations
9.
Adenis, Antoine, Katalin Boér, P. Escudero, et al.. (2008). AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy. Journal of Clinical Oncology. 26(15_suppl). 4114–4114. 14 indexed citations
10.
Horti, J, Anders Widmark, Ingela Turesson, et al.. (2008). A RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE II STUDY OF VANDETANIB PLUS DOCETAXEL / PREDNISOLONE IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER. European Urology Supplements. 7(3). 231–231.
11.
Pover, G., et al.. (1997). Fosinopril national survey: a post-marketing surveillance study of fosinopril (Staril) in general practice in the UK.. PubMed. 51(6). 394–8. 7 indexed citations
12.
McDonald, Christine F., G. Pover, & G K Crompton. (1988). Evaluation of the combination inhaler of salbutamol and beclomethasone dipropionate in the management of asthma. Current Medical Research and Opinion. 11(2). 116–122. 4 indexed citations
13.
Pover, G., et al.. (1988). Evaluation of a Breath Operated Powder Inhaler. Journal of International Medical Research. 16(3). 201–203. 29 indexed citations
14.
Pover, G., et al.. (1986). Comparison of the Effects of Sequential or Simultaneous Administration of Salbutamol and Beclomethasone Dipropionate. Respiration. 50(2). 83–87. 3 indexed citations
15.
Beswick, Kim, G. Pover, & Shirlene Sampson. (1986). Long-term regularly inhaled salbutamol. Current Medical Research and Opinion. 10(4). 228–234. 10 indexed citations
16.
Pover, G. & C. H. Dash. (1985). A new, modified form of inhaler ('Rotahaler') for patients with chronic obstructive lung disease.. PubMed. 4(2). 98–101. 8 indexed citations
17.
Pover, G., et al.. (1984). Assessment of a new combination inhaler containing salbutamol and beclomethasone dipropionate in the management of asthmatic patients.. PubMed. 65(19). 758–62. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tommasina Biscotti Breakdown of academic impact, for papers by Gemma Toledo Breakdown of academic impact, for papers by Masafumi Kataoka Breakdown of academic impact, for papers by Alexander Gaber Breakdown of academic impact, for papers by Minaxi Jhawer Breakdown of academic impact, for papers by Michela Quirino Breakdown of academic impact, for papers by Maria Rosa Cappelletti Breakdown of academic impact, for papers by Katherine L. Pogue–Geile Breakdown of academic impact, for papers by Antonella Ingrosso Breakdown of academic impact, for papers by J. Wisell
Rankless by CCL
2026